Dermatofibrosarcoma protuberans

Section editor transclusions Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.

1 regimens on this page 2 variants on this page

Guidelines

NCCN

• NCCN Guidelines - Dermatofibrosarcoma Protuberans (DFSP)

All lines of therapy

Imatinib monotherapy

Regimen variant #1, 400 mg/day

Study	Dates of enrollment	Evidence
Rutkowski et al. 2010 (SWOG S0345)	2005-2006	Phase 2, <20 pts

Targeted therapy

• Imatinib (Gleevec) 400 mg PO once per day

48-week course

Regimen variant #2, 800 mg/day

Study	Dates of enrollment	Evidence
Rutkowski et al. 2010 (EORTC 62027)	2004-2007	Phase 2, <20 pts (RT)

Targeted therapy

• Imatinib (Gleevec) 400 mg PO twice per day

Continued indefinitely, unless complete (R0) surgical resection became possible

References

1. EORTC 62027: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00085475
2. SWOG S0345: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00084630